“The Adventure Jar: A Story of Magic for Families Living with Metastatic Breast Cancer” is intended for children ages three to eight. The book follows the story of a family affected by metastatic breast cancer as they discover that even through the challenges of their mom’s diagnosis – involving inevitable change, uncertainty and disappointment – there is magic to be found in time shared together.​

Family life can be upended when a parent has cancer, and it can be difficult for parents to bear witness to the impact it can have on young children – creating a crucial need for resources to help navigate the challenging emotions that follow.

The Adventure Jar, led by Gilead Sciences, was created in collaboration with eight diverse members of the metastatic breast cancer (MBC) community and professionals, including a psychiatrist, to help families impacted by MBC.​

Among these collaborators is Gilead Patient Ambassador Lauren Huffmaster. She was diagnosed with MBC at 37 years old and struggled with the emotional impact cancer had on her husband and three young daughters, who were two, four and six at the time. Nearly a decade since her diagnosis, MBC continues to shape the lives of her daughters, but they’ve made it a habit to redefine their circumstances.

Breast cancer is the most commonly diagnosed cancer and leading cause of cancer death among women aged 20 to 49 years in the US[ Siegel, R. L., Miller, K. D., Wagle, N. S., & Jemal, A. (2023). Cancer statistics, 2023. CA: A Cancer Journal for Clinicians, 73(1), 17–48. https://doi.org/10.3322/caac.21763.​

MBC is the most advanced stage of breast cancer that has spread to other areas of the body, most often the bones, lungs, liver or brain.​[ Metastatic Breast Cancer Facts and Statistics. (n.d.). Susan G. Komen®. Retrieved June 14, 2024, from https://www.komen.org/breast-cancer/facts-statistics/what-is-breast-cancer/metastatic-breast-cancer/ It’s a lifelong disease, and treatment is an ongoing reality that doesn’t go away for most people.​ As younger women are being diagnosed with MBC at an alarming rate, this means that families, including many young children, are increasingly impacted.

#adventurejar #cancer #breastcancer

The post HELPING FAMILIES IMPACTED BY BREAST CANCER FIND MAGIC WITH “THE ADVENTURE JAR” appeared first on Good News!.

Victoria Schneps Yunis
President and Co-Publisher
Dan’s Papers

Join us for an oceanside evening!
Saturday, August 26, 2023

6:30 – 10:30 PM Cocktails, Dinner & Dancing
10:30 – 11 :30 PM Bonfire

Bridgehampton Tennis & Surf Club
231 Midocean Drive, Bridgehampton, NY 11976

Cuisine by Robbins Wolfe

For Tickets and More Information please visit: https://bit.ly/3E5JZSR

Gala Chair
Jean Shafiroff

Host Committee
Ingrid Arneberg
Stanley Baumblatt and Chaz Austin Autumn Chirlin
Lynne Chirlin
Sam Eskenazi
Yubal Marquez Fleites
Dede Gotthelf and Terry Moan John Graham
Monica Graham
Roberta Kaplan and Rachel Lavine Patti Kenner
Jane Krieger and Neil Bersin
Bridget LeRoy and Eric Johnson
Jackie Lowey and David Kuperschmid
Gianpiero D. Palermo
Rolise Rachel
Jodi and Jack Wasserman
Cathy and Norman Yohay

Young Professionals Host Committee
Co-Chairs
Sarah Alvarez
Elena Gibbs
Shola Farber
Trisha Guillen
Scott Kaufman
Katie McEntee
Sara Shala

The Ellen Hermanson Foundation Board of Directors
Julie Ratner, Ed.D,
President Ann Ciardullo,
Vice President Cathy Tweedy,
Secretary Hugo Moreno,
Treasurer Constance Chen,
MD Melissa Cohn
Amanda Star Frazer,
JD Hope
Klein Langer
James Levin
Thuyen Nguyen
Eileen Rappaport
Dee Rivera
Anne Tschida Gomberg, Executive Director

The Ellen Hermanson Foundation is a 501(c)(3) charitable organization that ensures access to breast health care and empowers people effected by cancer.
Proceeds benefit the Ellen Hermanson Breast Center at Stony Brook Southampton Hospital.

#ellenhermanson #ellenhermansonfoundation #summergala #summergala2023 #breasthealth #healthcare #cancer #ednakapenhas #southhampton #victoriaschnepsyunis #oceanside #robbinswolfe

The post The Ellen Hermanson Foundation Summer Gala 2023, ensures access to breast health care and empowers people effected by cancer appeared first on Good News!.

Current research suggests that a reduction in breast cancer screenings at the beginning of the COVID-19 pandemic may have contributed to fewer early-stage and more late-stage breast cancer diagnoses in 2020 (latest statistics available) than in 2019, according to a study published by the journal JAMA Network Open.3

Many people experienced delayed or cancelled mammograms because of the pandemic, and these disruptions may have contributed to later-stage breast cancer diagnoses, when the disease is more difficult to treat.3,4

While mammography screenings rebounded overall by July 2020, the cumulative deficit of missed mammograms may have important public health consequences,5 including the furthering of health disparities.6

Since 2021, breast cancer diagnoses have exceeded lung cancer diagnoses, becoming the most diagnosed cancer worldwide.7,8

In the United States, it is estimated that about 287,850 women in 2022 will be diagnosed with breast cancer.9 Breast cancer is the most commonly diagnosed cancer among women in the U.S., and this year it’s estimated that about 30% of all newly diagnosed cancers in women will be breast cancers.10

For those facing a breast cancer diagnosis, the treatment that follows can be challenging and time consuming. Additionally, the type of breast cancer a patient has — including triple negative, HER2+ or HR+ — impacts the type of treatment they’ll receive.

Dr. Ahmed Elkhanany, a breast cancer expert at the University of Alabama at Birmingham, will discuss the latest news surrounding delays in breast cancer screenings and some of the recent treatment options. A patient share her experience too.

Interview courtesy: Genentech

1 American Cancer Society. American Cancer Society Recommendations for the Early Detection of Breast Cancer. https://www.cancer.org/cancer/breast-cancer/screening-tests-and-early-detection/american-cancer-society-recommendations-for-the-early-detection-of-breast-cancer.html. Accessed June 9, 2022.
2 American Cancer Society. Survival Rates for Breast Cancer. https://www.cancer.org/cancer/breast-cancer/understanding-a-breast-cancer-diagnosis/breast-cancer-survival-rates.html. Accessed June 9, 2022.
3 Zhou J, et al. Comparison of Early- and Late-Stage Breast and Colorectal Cancer Diagnoses During vs Before the COVID-19 Pandemic. JAMA Network Open. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2789064. Accessed June 1, 2022.
4 Elek P, et al. Effects of lower screening activity during the COVID-19 pandemic on breast cancer patient pathways: Evidence from the age cut-off of organized screening. Health Policy. https://www.sciencedirect.com/science/article/pii/S0168851022001257?via%3Dihub. Accessed June 9, 2022.
5 Sprague B, et al. Changes in Mammography Utilization by Women’s Characteristics during the First 5 Months of the COVID- 19 Pandemic. JNCI. 29 March 2021. https://academic.oup.com/jnci/advance-article/doi/10.1093/jnci/djab045/6184869.
Accessed June 1, 2022.
6 DeGroff A, et al. COVID-19 impact on screening test volume through the National Breast and Cervical Cancer early detection program, January–June 2020, in the United States. Preventive Medicine. 2021. https://www.sciencedirect.com/science/article/pii/S0091743521001432?utm_campaign=11a0a4d458MR_COPY_02&utm_medium=email&utm_source=STAT+Newsletters&utm_term=0_8cab1d7961-11a0a4d458-153427414. Accessed June 1, 2022.
7 World Health Organization. Breast cancer now most common form of cancer: WHO taking action. https://www.who.int/news/item/03-02-2021-breast-cancer-now-most-common-form-of-cancer-who-taking-action. Accessed June 1, 2022.
8 International Agency for Research on Cancer. All-cancers fact-sheet. https://gco.iarc.fr/today/fact-sheets-cancers. Accessed June 10, 2022.
9 National Cancer Institute, The Surveillance, Epidemiology, and End Results (SEER). Cancer Stat Facts: Female Breast Cancer. https://seer.cancer.gov/statfacts/html/breast.html. Accessed June 10, 2022.
10 BreastCancer.org. U.S Breast Cancer Statistics. https://www.breastcancer.org/symptoms/understand_bc/statistics. Accessed June 10, 2022.

#breastcancer #ahmedelkhanany #pandemic #melissa #women #survivalrates #covid #delayed #cancelmammograms #cancelledmammograms #disruptions #genentech #screening #treatment #experience

The post DROP IN EARLY BREAST CANCER DIAGNOSES TIED TO PANDEMIC appeared first on Good News!.

PEACE DAY 2022 NEEDS YOUR HELP: We have been given till April 15 to raise money and detail our CENTRAL PARK, GREAT LAWN FOR SEPTEMBER 10, 11, 2022 EVENT FOR OUR WWW.PEACEDAYPARTY.ORG AND THEN TIMES SQUARE for September 21. DO YOU KNOW ANYONE WHO WOULD BENEFIT AND RECEIVE THE RECOGNITION FROM THE BEING OUR BENEFACTOR/PATRON AS THE PRESENTER OF PEACE DAY 2022??? FOR OUR NONPROFIT WORLDWIDE INITIATIVE, 193 COUNTRIES AGREED IN THE UN? WE WILL GO TO ALL OF THEM FOR OUR BROADCAST!

Budget and details furnished upon request. Call/ text Paul 9176871790

SMALL MONEY FOR: PAUSING THE WORLD, FOCUSING ON HUMAN SECURITY, A WATER WORLDWIDE MESSAGE AND ACTION WORTH EVERY CENT! 12 NOON SEPTEMBER 21 PAUSE THE WORLD AND THEN A WORLDWIDE PEACE PARTY!

COVID TESTS AVAILABLE: We also have Covid Tests for sale if you know someone that needs them in a larger quantity, call Paul

LET’S GROW TOGETHER. GOOD NEWS MOTTO: ALL WE ARE IS WHAT WE ARE WITH EACH OTHER. ZEAL

For more information contact:

Paul Sladkus 212 647 1212

New York, NY, Montauk, NY

PS – SPECIAL OPPORTUNITY FOR OUR FRIENDS AND MEMBERS: Looking for a vacation rental, SHORT TERM, in Montauk, NY. Call Paul. https://goodnewsplanet.com/montauk-manor-rental-suite-403-paul-sladkus/

The post GoodNewsLetter: KLECKT NFT/The Phantom, Breast Cancer Trials, Peace Day…02/18/22 appeared first on Good News!.

NIH study advances personalized immunotherapy for metastatic breast cancer

An experimental form of immunotherapy that uses an individual’s own tumor-fighting immune cells could potentially be used to treat people with metastatic breast cancer, according to results from an ongoing clinical trial led by researchers at the National Cancer Institute’s (NCI) Center for Cancer Research, part of the National Institutes of Health. Many people with metastatic breast cancer can mount an immune reaction against their tumors, the study found, a prerequisite for this type of immunotherapy, which relies on what are called tumor-infiltrating lymphocytes (TILs).

In a clinical trial of 42 women with metastatic breast cancer, 28 (or 67%) generated an immune reaction against their cancer. The approach was used to treat six women, half of whom experienced measurable tumor shrinkage. Results from the trial appeared Feb. 1, 2022, in the Journal of Clinical Oncology.

“It’s popular dogma that hormone receptor–positive breast cancers are not capable of provoking an immune response and are not susceptible to immunotherapy,” said study leader Steven A. Rosenberg, M.D., Ph.D., chief of the Surgery Branch in NCI’s Center for Cancer Research. “The findings suggest that this form of immunotherapy can be used to treat some people with metastatic breast cancer who have exhausted all other treatment options.”

Immunotherapy is a treatment that helps a person’s own immune system fight cancer. However, most available immunotherapies, such as immune checkpoint inhibitors, have shown limited effectiveness against hormone receptor–positive breast cancers, which are the majority of breast cancers.

The immunotherapy approach used in the trial was pioneered in the late 1980s by Dr. Rosenberg and his colleagues at NCI. It relies on TILs, T cells that are found in and around the tumor.

TILs can target tumor cells that have specific proteins on their surface, called neoantigens, that the immune cells recognize. Neoantigens are produced when mutations occur in tumor DNA. Other forms of immunotherapy have been found to be effective in treating cancers, such as melanoma, that have many mutations, and therefore many neoantigens. Its effectiveness in cancers that have fewer neoantigens, such as breast cancer, however, has been less clear.

The results of the new study come from an ongoing phase 2 clinical trial being carried out by Dr. Rosenberg and his colleagues. This trial was designed to see if the immunotherapy approach could lead to tumor regressions in people with metastatic epithelial cancers, including breast cancer. In 2018, the researchers showed that one woman with metastatic breast cancer who was treated in this trial had complete tumor shrinkage, known as a complete response.

In the trial, the researchers used whole-genome sequencing to identify mutations in tumor samples from 42 women with metastatic breast cancer whose cancers had progressed despite all other treatments. The researchers then isolated TILs from the tumor samples and, in lab tests, tested their reactivity against neoantigens produced by the different mutations in the tumor.

Twenty-eight women had TILs that recognized at least one neoantigen. Nearly all the neoantigens identified were unique to each patient.

“It’s fascinating that the Achilles’ heel of these cancers can potentially be the very gene mutations that caused the cancer,” said Dr. Rosenberg. “Since that 2018 study, we now have information on 42 patients, showing that the majority give rise to immune reactions.”

For the six women treated, the researchers took the reactive TILs and grew them to large numbers in the lab. They then returned the immune cells to each patient via intravenous infusion. All the patients were also given four doses of the immune checkpoint inhibitor pembrolizumab (Keytruda) before the infusion to prevent the newly introduced T cells from becoming inactivated.

After the treatment, tumors shrank in three of the six women. One is the original woman reported in the 2018 study, who remains cancer free to this day. The other two women had tumor shrinkage of 52% and 69% after six months and 10 months, respectively. However, some disease returned and was surgically removed. Those women now have no evidence of cancer approximately five years and 3.5 years, respectively, after their TIL treatment.

The researchers acknowledged that the use of pembrolizumab, which has been approved for some early-stage breast cancers, may raise uncertainties about its influence on the outcome of TIL therapy. However, they said, treatment with such checkpoint inhibitors alone has not led to sustained tumor shrinkage in people with hormone receptor–positive metastatic breast cancer.

Dr. Rosenberg said that with the anticipated opening early this year of NCI’s new building devoted to cell-based therapies, he and his colleagues can begin treating more individuals with metastatic breast cancer as part of the ongoing clinical trial. He noted that this new immunotherapy approach could potentially be used for people with other types of cancer as well.

“We’re using a patient’s own lymphocytes as a drug to treat the cancer by targeting the unique mutations in that cancer,” he said. “This is a highly personalized treatment.”

About the Center for Cancer Research (CCR): CCR comprises nearly 250 teams conducting basic, translational, and clinical research in the NCI intramural program — an environment supporting innovative science aimed at improving human health. CCR’s clinical program is housed at the NIH Clinical Center — the world’s largest hospital dedicated to clinical research. For more information about CCR and its programs, visit ccr.cancer.gov.

About the National Cancer Institute (NCI): NCI leads the National Cancer Program and NIH’s efforts to dramatically reduce the prevalence of cancer and improve the lives of cancer patients and their families, through research into prevention and cancer biology, the development of new interventions, and the training and mentoring of new researchers. For more information about cancer, please visit the NCI website at cancer.gov or call NCI’s contact center, the Cancer Information Service, at 1-800-4-CANCER (1-800-422-6237).

About the National Institutes of Health (NIH): NIH, the nation’s medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit nih.gov

#cancer #rosenberg #national #institute #health #research #breast #immunotherapy #patients #metastatic #tumor #fight #lymphocytes #oncology #infiltrating #immune #response #cells #dna #science

The post National Cancer Institute Researcher — Exciting Finding in Fight Against Breast Cancer (And Potentially Others) appeared first on Good News!.

http://instagram.com/EveryDayforMBC

What should people be aware of in terms of breast cancer screening and COVID-19?

Can you tell us about your experience treating people diagnosed with MBC? What are the biggest unmet needs and how is the treatment landscape changing?

What are some of the major challenges in MBC today?

Why is it so important for women to not delay routine mammogram screenings?

Where can the MBC community go for more information and support?

BIO-Dr. Bhuvana Ramaswamy is a breast cancer oncologist, physician-scientist at the James. She leads the breast medical oncology section and is also the Chair of the Clinical Scientific Review Committee for the James. Her research interests are in drug-resistance and racial disparities in cancer outcomes. Her lab focuses on finding the molecular link between breastfeeding and risk of breast cancer. She was named as one the “top 27 breast medical oncologists” in the nation by Forbes in 2017 and recently received the Mazzaferri-Ellison Society of Master Clinicians Award.

http://instagram.com/EveryDayforMBC

Interview is Courtesy: Seagen

#breast #cancer #disease #metastatic #covid #mammograms #doctors #ramaswarmy #treating #diagnosed #mbc #treatment #screening #community #support #bhuvana #oncologist #drug #scientist #seagen

The post Women diagnosed with a certain type of breast cancer face a vastly different outlook than others with the disease. appeared first on Good News!.

#deepa #halaharvi #breast #cancer #chemotherapy #therapies #hormone #blocking #lymph #nodes #rxponder #menopausal #effects #oncotype #dx #recurrence #genomic #benefit #risk #exact

The post October is Breast Cancer Awareness Month NEW STUDY CONFIRMS EVEN MORE WOMEN WITH BREAST CANCER CAN SKIP CHEMOTHERAPY appeared first on Good News!.

REGISTER HERE FOR NOVEMBER 17

American Friends of Rabin Medical Center (AFRMC) is a 501 (c) (3) nonprofit charitable organization that was established in 1995. Through a variety of programs and fundraisers across the United States, the funds raised by American Friends of Rabin Medical Center benefit AFRMC in furtherance of its mission to fund charitable, educational and scientific purposes at Rabin Medical Center. A portion of all funds raised are used for AFRMC operations. Israel’s Rabin Medical Center in Petach Tikvah, named after former Prime Minister Yitzhak Rabin, is the pride of Israel, serving the needs of one million patients annually without regard to ethnicity, nationality or religion.

Unsubscribe
American Friends of Rabin Medical Center
636 Broadway, Ste. 618, New York, NY 10012

The post Hear Robert Siegel & Breast Cancer Experts 10/28 @4 pm ET appeared first on Good News!.

Nancy Mikaelian Madey shares her personal health story on moving life forward after a concerning health condition. Good News interviewed Nancy 20 years ago with her book Facing Fear. Nancy also writes for Chicken Soup for the Soul. She is special.

The post A Story from Metastatic Breast Cancer to a Whole New Life appeared first on Good News!.

We seek to grow and serve a vibrant, global footwear industry, where doing business in New York is profitable and easy for our membership, and where the industry strengthens through education and unites in charity.

Our mission is to:

Serve and grow the footwear industry by making it easy and fun for buyers and sellers of shoes to do business in New York.
Drive innovation to make the buying and selling of shoes easier.
Strengthen the industry through education.
Unite the industry in charity.
Propel the industry forward.
New York City is the heart of fashion and the center of global business. That’s why we’re dedicated to growing the footwear industry by making it easy to do business in New York. The New York Shoe Expo brings together retailers, brands, designers, buyers and sellers four times a year – all right here in New York City.

Giving back is a huge part of our mission at FFANY. FFANY unites the industry in charity by rallying footwear leaders around important causes including, in particular, breast cancer research.

Growing an industry takes more than just business opportunities. At FFANY, we understand the need to strengthen the industry through education. From scholarships and workshops to e-learning courses, FFANY is paving the way for a new generation for footwear professionals.
New York, United States Rating:★ 4.0

The post Fashion Footwear Association of New York (FFANY) appeared first on Good News!.